Delcath Systems, Inc. (DCTH)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 3
Do Nothing: no qualifying entry — a pullback/oversold limit is countertrend (price 15.36 < SMA50 15.94 with MACD -0.16 < 0, trend-alignment gate) and no breakout stop qualifies (settled breakout levels 15.82/15.97 yield R/R 0.76/0.69, below the 1.0 floor).
Company overview
Delcath Systems, Inc. is a company focused on interventional oncology, developing treatments for liver cancers in the US and Europe. Its main product, the HEPZATO KIT, delivers high-dose chemotherapy directly to the liver, aiming to reduce systemic exposure and side effects. The company also markets a similar system in Europe under the CHEMOSAT brand.
Fundamental
fairDelcath Systems shows strong revenue growth but faces challenges with thin profitability and high valuation multiples.
Mixed fundamentals with a high-quality core: revenue compounding (FY2025 +129%; H1 2026 +24.7% YoY), ~87% gross margins, $95.9M cash/investments and no debt, and FY2025 was the first profitable year with $22.5M operating cash flow. But GAAP profitability is thin and reinvestment-heavy (TTM net margin 0.56%, ROIC -0.6%), stock-based compensation runs ~28% of revenue, and the stock trades at ~1,036x trailing earnings and ~30x free cash flow while both DCF models print breakdown-level negatives. Verdict: a promising, execution-dependent commercial-stage medtech with material reimbursement, customer-concentration and dilution uncertainties — mixed rather than compelling.
Sentiment
fairSentiment is mildly positive with no fresh catalysts, as recent momentum is based on past events.
Dominant signal is constructive tape momentum — a fresh 52-week high and best session in ~15 months on 2026-10-07 (technical, rumored) — layered on an already-digested commercial narrative (Q2 revenue up ~21% with raised FY guidance, 2026-08-06). The 14-day media read is mildly positive (polarity_score ≈ +0.25, n=4) while the 30–90-day sentiment delta is indeterminate (baseline scored sample below threshold); the Red-Flag Screen is clean and no caps apply, with no confirmed forward-dated catalyst on the calendar.
Technical
fairThe stock is in a corrective phase, trading below key moving averages with no actionable entry points.
Chart quality 3/5 (mixed). Price 15.36 trades below the near-term stack (SMA20 15.83, SMA50 15.94, EMA9 15.47, EMA21 15.70, WMA9 15.39, WMA21 15.65) with MACD negative (-0.16/-0.06/-0.10), RSI 45.2 and weak ADX 18.3 — a two-month corrective downtrend from the 17.42 (08-11) high now attempting a bounce off the 14.52 (10-08) low. Offsetting bullish structure: price holds ~28% above a rising SMA200 (12.01) and above DEMA14/TEMA14, and the 10-09 session (+2.1%) closed near its high above the session VWAP 15.20. Trade rejected on entry mechanics, not chart breakage: any pullback/oversold limit is countertrend under the trend-alignment gate (price < SMA50 and MACD < 0), and every settled breakout trigger (15.82/15.97/16.02) yields R/R of only 0.67-0.76 against the structure-based stop 14.41, below the 1.0 floor. Do Nothing.
You’re looking at 2026-10-09 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

